ArticleThe oncologist2022
Correction to: Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.